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Multicenter randomized clinical trial of supervised
exercise therapy with or without feedback versus
walking advice for intermittent claudication
Saskia P. A. Nicolaï, MD, PhD,a Joep A. W. Teijink, MD, PhD,b and Martin H. Prins, MD, PhD,c on
behalf of the Exercise Therapy in Peripheral Arterial Disease (EXITPAD) study group,* Heerlen,
Eindhoven, and Maastricht, The Netherlands
Objective: The initial treatment for intermittent claudication is supervised exercise therapy (SET). Owing to limited
capacity and patient transports costs of clinic-based SET, a concept of SET provided by local physiotherapists was
developed. We hypothesized that provision of daily feedback with an accelerometer in addition to SET would further
increase walking distance.
Methods. This multicenter randomized trial was set in vascular surgery outpatient clinics and included 304 patients with
intermittent claudication. Patients were randomized to exercise therapy in the form of “go home and walk” advice (WA),
SET, or SET with feedback. Local physiotherapists provided SET. The primary outcome measure was the change in
absolute claudication distance. Secondary outcomes were the change in functional claudication distance and results on the
Walking Impairment Questionnaire (WIQ) and Short-Form 36 (SF-36) Health Survey after 12 months.
Results: In 11 centers, 102, 109, and 93 patients were included, respectively, in the WA, SET, and SET with feedback
groups, and data for 83, 93, and 76, respectively, could be analyzed. The median (interquartile range) change in walking
distance between 12 months and baseline in meters was 110 (0-300) in the WA group, 310 (145-995) in the SET group,
and 360 (173-697) in the SET with feedback group (P < .001 WA vs SET). WIQ scores and relevant domains of the
SF-36 improved statistically significantly in the SET groups.
Conclusions: SET is more effective than WA in improving walking distance, WIQ scores, and quality of life for
patients with intermittent claudication. Additional feedback with an accelerometer did not result in further
improvement. SET programs should be made available for all patients with intermittent claudication. ( J Vasc Surg
2010;52:348-55.)Atherosclerotic disease of the arteries of the lower
extremities resulting in walking impairment, typically de-
scribed as muscular leg pain during exercise and relieved by
rest, is defined as intermittent claudication. According to
national and international guidelines, the initial treatment
of patients with intermittent claudication is (supervised)
exercise therapy (SET) combined with cardiovascular risk
management.1,2
The beneficial effect of exercise therapy is well known.
Various exercise programs have been shown to improve
maximal walking distance by 150%.3 Exercise therapy is
often prescribed in the form of “go home and walk” advice;
however, compliance with this strategy is known to be
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348low.4 Although a Cochrane review suggested a benefit of
SET over non-SET programs,5 most of the reviewed stud-
ies were small and SET was offered in a clinical setting,
either in an outpatient clinic for physiotherapy and rehabil-
itation or in a vascular laboratory. Clinic-based patient care
has several disadvantages, including limited capacity of the
institution and high transportation costs for the patient.
For this reason, a network of physical therapists providing
SET in settings closer to patients’ homes was developed.6
The first results suggested that SET provided by local
physical therapists could be at least as effective as SET in a
clinical setting.7,8
Although SET offers the benefit of adequate (weekly)
coaching, the overall superior effect of SET is likely partially
due to improved compliance with the exercise regimen. We
hypothesized that the use of an accelerometer, which pro-
vides daily therapy feedback, with SET would afford more
effective coaching and might result in a further increase in
walking distance. Hence, a multicenter randomized clinical
trial was conducted to compare “go home and walk”
exercise therapy, as is still common practice, with SET
provided by local physical therapists with or without daily
therapy feedback.
METHODS
This study was approved by the Institutional Review
Board (IRB) of the AtriumMedical Center and by the IRBs
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gov (NCT00279994).
Patients. Eleven outpatient vascular surgery clinics dis-
tributed throughout The Netherlands participated in the Ex-
ercise Therapy in Peripheral Arterial Disease (EXITPAD)
study.
Patients with stage II peripheral arterial disease accord-
ing to Fontaine, who were considered for conservative
treatment, were eligible. Inclusion criteria were an ankle-
brachial index (ABI) 0.9 and an absolute claudication
distance (ACD) of 500 meters as assessed with a stan-
dardized treadmill test. Exclusion criteria included a prior
SET program for intermittent claudication, previous pe-
ripheral vascular intervention, insufficient command of the
Dutch language, serious cardiopulmonary limitations
(New York Heart Association functional class III or IV),
previous lower limb amputation, psychiatric instability, and
any other serious comorbidity that might hinder physical
training. Chronic obstructive pulmonary disease (COPD)
and coronary heart disease, defined as angina pectoris or
myocardial infarction, were recorded by medical history.
Eligible patients were asked to participate and provided
written informed consent.
Randomization and blinding. Patients were ran-
domized to exercise therapy in the form of a walking advice
(WA) only, SET provided by local community-based phys-
ical therapists, or SET provided by local physical therapists
with the additional use of an accelerometer to provide daily
feedback. Randomization took place centrally by telephone,
and numbers were generated by a computer-generated block
randomization list (block size 9, first block opened at
random) stratified by center.
The local vascular surgeons enrolling patients, the pa-
tients, and their physical therapists, if applicable, were
inherent to the study design and so were not blinded to
group assignment. However, the study personnel who ad-
ministered the treadmill tests and collected the question-
naires were blinded for previous outcomes and group
assignment. Patients were instructed to refrain from com-
menting on treatment assignment and therapy progress dur-
ing the assessments.
Interventions. Before randomization, all patients re-
ceived, according to the guidelines, cardiovascular risk
management by their enrolling vascular surgeon, cholesterol-
lowering medication, antiplatelet therapy, the advice to
stop smoking, and modification of other atherosclerotic
risk factors that were present.1
Patients randomized to the WA group received verbal
walking advice and a brochure distributed by the Patients
Association of Vascular Diseases explaining exercise therapy.9
Patients were instructed by their attending vascular sur-
geons who enrolled them in the study to complete three
training sessions per day. During each session, maximum
pain level should be reached three times. Hence, patients
were advised to walk until maximum pain level nine times a
day, divided in three sessions.
Patients randomized to the SET groups were referred
to a local physical therapist. For each participating center, anetwork of local physical therapists was trained in SET
according to Royal Dutch Society for Physical Therapy and
the Dutch Institute of Allied Health Care.6 An average
network consists of 20 to 30 physical therapists equally
distributed throughout the region of the hospital. The
educational program ensured that all patients received SET
according to the guidelines of the Royal Dutch Society for
Physical Therapy.10
Patients were instructed in the same way as those in the
WA group but were also referred to a physical therapist for
a supervised program. The main goal was to increase the
patients’ walking distance by interval training up to sub-
maximum pain with short walking intervals. The program
also consisted of walking pattern improvement and en-
hancement of endurance and strength. Patients generally
started with a frequency of two to three sessions of 30
minutes weekly. This was tailored to the individual need of
the patient during the treatment year. In conformity with
the WA group, all SET patients were encouraged to per-
form at least three walking sessions every day.
Patients assigned to SET with feedback additionally
received a Personal Activity Monitor (PAM) accelerometer
(PAM B.V., Doorwerth, The Netherlands).11,12 The PAM
is a performance-based accelerometer to assess physical
activity during normal life. PAM measures the acceleration
of the body with an accelerometer and expresses the mea-
sured movements in a cumulative score that is continuously
displayed for feedback. The accelerometer measures the
force on the body (up-down direction) and can distinguish
between an intensive movement, such as a step during
running, and a less-intensive movement, such as a step
during walking, expressed as a small increase in score or a
great increase in score, respectively. The patient was in-
structed to wear this instrument continuously during the
day for 1 year and to record the PAM scores every day.
Physical therapists used the PAM scores to give feedback to
patients regarding their walking efforts outside the SET
program, and patients were encouraged to reach higher
PAM scores the following days.
The manufacturer (PAM B.V.) provided us with tech-
nical support. PAM B. V. did not have access to outcome
data and did not participate in data analysis or preparation
of the manuscript.
Outcome measurements. The primary outcomemea-
surement was the change in absolute claudication distance
(ACD). Secondary outcome measurements were the change
in functional claudication distance (FCD), the Walking
Impairment Questionnaire (WIQ), and the Short-Form 36
(SF-36) Health Survey. After 3, 6, 9, and 12 months of
follow-up, walking distance on the treadmill was assessed,
and the WIQ and SF-36 were completed.
The ACDwas defined as themoment the patient had to
stop walking due to a maximum pain level. The FCD was
defined as the moment the patient preferred to stop walk-
ing due to the pain. Treadmill testing is the most com-
monly used quantitative measure to assess walking ability.1
ACD13 and FCD14 are both reliable tools to evaluate
walking distance in patients with intermittent claudication.
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gressive treadmill test with a constant speed of 3.2 km/h
starting with 0% inclination, increasing every 2 minutes by
2%.13,15 For practical reasons, the maximum inclination
was 10% and the maximum duration of the test was 30
minutes (1600 meters).
TheWIQ is a short, validated questionnaire for patients
with peripheral arterial disease that is easy to complete.16-18
It contains three domains to assess walking impairment:
walking distance, walking speed, and stair climbing. For
each domain, a subscore of the Likert items was calculated.
The mean of these domains represents the total WIQ
score.19 We used a self-administered revised version of the
WIQ18 recently adapted and validated for the European
metric system and the Dutch language.20
The SF-36 is a general, frequently used quality-of-life
questionnaire validated for the Dutch language.21 The
SF-36 contains eight subscales that reflect mental and
physical functioning—physical functioning, social func-
tioning, physical role impairment, emotional role impair-
ment, mental health, vitality, pain and general health expe-
rience—and is calculated with a scoring algorithm.22
Statistical analysis. With a sample size of 81 patients
per treatment arm, the trial had a power of 80%, to dem-
onstrate an increase in ACD of 150 meters (standard devi-
ation [SD], 300meters) with two-sided  0.025. Assum-
ing a 15% to 20% withdrawal rate, 100 patients in each
group had to be included.
Analysiswasconductedaccordingto themodified intention-
to-treat principle. The analysis included all data from pa-
tients who were randomized and completed the treadmill
assessment for quantifying walking distance after 12
months of treatment. Patients who transferred to another
group or patients who stopped the intervention but per-
formed the treadmill assessment were analyzed in their
original group. The analysis excluded patients who
dropped out 12 months of follow-up.
Categoric variables were presented as frequencies with
percentages, and continuous variables were presented as
means  SD when normally distributed and as medians
with interquartile ranges (IQR) in case of a skewed distri-
bution. For baseline characteristics, comparisons between
groups were performed using one-way analysis of variance
(ANOVA) for continuous variables, and a 2 test was used
for categoric variables.
Missing values of walking distances at 3, 6, and 9
months were imputed based on a multivariate linear regres-
sion analysis. A backward elimination method was used to
identify variables included in the final regression equation
to impute data. Baseline walking distance, age, COPD, and
cardiac disease as variables yielded R2s for the ACD of
between 22.1% and 28.1%, which are comparable with an
earlier report.23 Increases in walking distances within
groups were analyzed with a repeated measurements
ANOVA. Changes in walking distances between the groups
over time were analyzed with a Wilcoxon rank-sum test.
Missing values of the WIQ and SF-36 were imputed
with a mean substitution method. Differences of the WIQand SF-36 within a group were analyzed with repeated
measurements ANOVA. Statistical significance between
the WA and SET with or without feedback group of the
WIQ and the SF-36 was analyzed with repeated measure-
ments analysis of covariance (ANCOVA) with the baseline
measurement as covariate. Analyses were performed with
SPSS 15.0 software (SPSS Inc, Chicago, Ill).
RESULTS
Study population. Between December 2005 and
May 2008, 304 patients were enrolled in the study, con-
sisting of 102 patients in the WA group, 109 in the SET
group, and 93 in the SET with feedback group. The
number of included patients per center is shown in the
Appendix. Follow-up endedMay 2009. Baseline character-
istics were generally well balanced among the study groups;
there were more men in the SET group and more current
smokers in the WA group. Patients in the three groups had
comparable median baseline walking distances (Table I).
Adherence to the intervention and follow-up. One
patient in the WA group did not start with the study after
randomization. Five patients randomized to the WA group
started with SET during the course of the study, two on
their own initiative and three after a prescription from their
vascular surgeon. These patients were, based on the applied
modified intention-to-treat principle, analyzed in the WA
group. Fifteen patients were lost to follow-up and 3 died,
leaving 83 patients for analysis (Fig 1).
In the SET group, 26 patients discontinued the pro-
gram: 12 were lost to follow-up, 4 died, and the remaining
11 stopped SET for other reasons than satisfaction with the
regained walking distance but were eligible for analysis.
Lack of motivation was the main recorded reason to dis-
continue the program. In total, 93 patients in the SET
group were analyzed.
In the SET with feedback group, 3 patients did not
start with the study and 27 stopped the SET program, of
whom 14 were lost to follow-up and 13 patients discontin-
ued the program but were eligible for analysis. Of the 76
analyzed patients, 22 (28.9%) reported not having used the
PAM accelerometer at all or only for part of the study year.
Because almost 30% reported nonuse of the PAM, we
decided to analyze the SET and SET with feedback group
together (n  169).
During the study, 9 patients (10.8%) of the WA group
and 13 (7.7%) of both SET groups together underwent a
peripheral vascular intervention due to worsening of com-
plaints or dissatisfaction with the results of the exercise
program (P  .38).
Walking distance. The median ACD for the patients
included in the modified intention-to-treat analysis in-
creased from 260 to 400 meters in the WA group and from
260 to 600 meters in the SET groups. The increase in
median FCD showed a similar pattern, from 150 to 320
meters in the WA group and from 150 to 460 meters in the
SET groups. The ACD and the FCD both increased signif-
icantly in all groups (Table II). Fig 2 presents the percent-
age of patients per group with an increase in ACD of100,
se; SE
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the WA group, 48.2% increased 100 meters and 18.1%
increased 500 meters; in the SET groups, this was 15.4%
and 34.4%, respectively. The median IQR meter increases
Table 1. Patient baseline characteristics
Variable
WA
(n  102)
Men, % 55.9
Age, mean (SD), y 66.9 (8.6)
BMI, mean (SD), kg/m2 28.2 (4.7)
ABI, mean (SD) 0.65 (0.17)
ACD, median (IQR), m 240 (160-345)
FCD, median (IQR), m 150 (90-250)
Smoking, %
Current smoking 47.1
Former smoker 41.2
Never smoked 9.8
Unknown 2
Diabetes mellitus, % 23.5
LE orthopedic disease, % 14.7
Coronary heart disease, % 27.5
CVA or TIA, % 12.7
COPD, % % 26.5
ABI, Ankle-brachial index; ACD, absolute claudication distance; COPD
functional claudication distance; IQR interquartile range; LE, lower extre
ischemic attack; WA, walking advice.
aBy 2 test.
bBy one-way analysis of variance.
Fig 1. Flow chart shows study details according to Con
Cerebrovascular accident; PAD, peripheral arterial diseain ACD and FCD were, respectively, 110 (0-300) and 100(0-310) in the WA group and 350 (152-810) and 300
(128-575) in the SET groups, respectively. Patients follow-
ing a SET program with or without feedback regained
significantly more walking distance (ACD, P .001; FCD,
SET SET with feedback
P value( n  109) (n  93)
72.5 60.2 .08a
.1 (9.0) 65.6 (10.5) .59b
.4 (4.2) 28.2 (5.1) .34b
7 (0.19) 0.67 (0.16) .63b
0 (167-395) 250 (160-340) .48b
0 (90-250) 150 (100-230) .75b
38.5 41.9 .28a
49.5 46.2 .42a
12 4.3 .20a
0 7.5
25.7 18.3 .47a
14.7 17.2 .84a
26.6 20.4 .43a
14.7 9.7 .58a
18.3 17.2 .22a
nic obstructive pulmonary disease; CVA, cerebrovascular disease; FCD,
SD, standard deviation; SET, supervised exercise therapy; TIA, transient
ted Standards of Reporting Trials statement.38,39 CVA,
T, supervised exercise therapy; WA, walking advice.66
27
0.6
26
15
, chro
mity;solidaP .001) than patients in the WA group. The SET groups
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152-366), more than the WA group. There was no differ-
ence in improvement of walking distances between the two
SET groups. Results did not substantially change after data
imputation. Similar results between the WA and SET
groups were obtained using ANCOVA with baseline walk-
ing distance as the covariate.
Walking Impairment Questionnaire. The total
WIQ score improved from 0.46 to 0.59 in the WA group
and from 0.47 to 0.67 in the SET group. A repeated
measurements ANCOVA between the WA and SET
groups showed significantly more improvement in favor of
the SET groups (P  .004; Table III). A Pearson correla-
tion coefficient of 0.396 (P .001) was found between the
change in ACD and the change in total WIQ score between
baseline and 12 months.
Quality of life. The physical summary score of the
SF-36 improved significantly within the SET groups (P 
.001). This was mainly due to improvements in the sub-
scales of physical functioning, physical role, and pain. The
physical summary score showed a trend toward improve-
ment in the SET groups compared with theWA group (P
.02). The subscale of physical functioning and pain showed
significant improvements in the SET groups compared with
the WA group. The mental health summary score did not
improve over time. The eight subscales and the physical and
mental health components of the SF-36 are presented in
Table II. Walking distances in meters (interquartile range
Group No. Baseline 3 mon 6 mon
WA 83
ACD 260 (160-370) 320 (210-500) 400 (230-63
FCD 150 (100-220) 230 (170-360) 320 (180-48
SET 169
ACD 260 (165-370) 530 (341-804) 610 (383-10
FCD 150 (95-245) 380 (255-555) 470 (280-66
ACD, Absolute claudication distance; FCD, functional claudication distanc
aRepeated measurements analysis of variance.
bMedian change in walking distance with interquartile ranges.
Fig 2. Percentage of patients is shown with walking distance im-
provement in meters of 100, 100-200, 200-300, 300-400, 400-
500, and 500 in the actual claudication distance in the walking
advice (WA) and supervised exercise therapy (SET) groups.Table III.DISCUSSION
The results of this multicenter randomized clinical trial
show that walking distances improved in the WA group,
but that SET, provided by local physical therapists, im-
proved walking distances, WIQ scores, and scores on rele-
vant domains of the SF-36 12 months. Compared with
simple walking and exercise instructions combined with
information leaflets, SET results in an increase of about 200
meters in the walking distance, which reflects a clinically
relevant improvement. The use of daily feedback by an
accelerometer was not associated with further improve-
ment.
The observed effect of SET vs WA on the ACD is well
in line with results of a Cochrane meta-analysis that calcu-
lated a difference of approximately 150 meters between
SET and unsupervised exercise programs in studies analyz-
ing a small number of patients.5 Similarly, six more recently
published small trials with between 14 and 70 patients
reportedmainly a benefit of SET over unsupervised exercise
programs on walking distance.24-29 Studies assessing the
effect of SET on quality of life expressed as relevant do-
mains of the SF-36 are scarce, and inconclusive published
data suggest that SET offers none or only modest improve-
ment on quality of life compared with unsupervised exer-
cise programs.5,28,30 Although patients who used an accel-
erometer for feedback might have been more active,31 a
recent meta-analysis suggests that training more than three
times per week does not provide further benefit for patients
with intermittent claudication.32
SET programs vary in setting, duration, and content.
Two meta-analyses found the optimal frequency was three
times a week32 or three times a week or more.33 There is no
consensus regarding the minimum duration of SET pro-
grams, with reported recommendations varying from 10 to
14 weeks34 and 12 to 24 weeks32 to 26 weeks.33 A
randomized trial evaluating various durations and frequen-
cies would be required to address this question satisfactorily
and optimize the intervention.
In this large randomized clinical, we were able to
demonstrate a beneficial effect of SET compared with WA
on walking distance. The benefits were apparent as early as
3 months after initiation of therapy and persisted for at least
12 months. More importantly, SET offered a sustained
9 mon 12 mon P valuea Changeb
473 (260-735) 400 (230-590) .001 110 (0-300)
380 (220-574) 320 (180-500) .001 100 (0-310)
620 (467-1155) 600 (435-1040) .001 350 (152-810)
493 (330-745) 460 (295-720) .001 300 (128-575)
, supervised exercise therapy; WA, walking advice.)
0)
0)
00)
8)
e; SETbenefit on the physical domains of quality of life, which was
as cov
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 2 Nicolaï et al 353not seen after unsupervised training. Participating in a trial
that stimulates physical activity affects patient behavior,35
and patients who were willing to participate in this study
might have had an intrinsic motivation to increase their
activity level that might limit generalizability. Finally, ow-
ing to the nature of the interventions, this was an open
study. We attempted to obtain an unbiased observation of
the ACD, but it is difficult to ascertain complete blinding of
this outcome measurement.
The results of this large randomized clinical trial are
consistent with a meta-analysis of previously performed
smaller studies.5 Both indicate that SET is an effective
treatment for intermittent claudication and should be of-
fered as first-line treatment. However, the availability of
SET in clinical practice is far from optimal.36,37 This can be
related to reimbursement policies of insurance companies
and availability of adequately trained professionals who can
provide SET. Hence, there seems to be an obligation for
professionals in the vascular field to take action to make this
effective intervention available for all patients with intermit-
tent claudication.
CONCLUSIONS
SET is more effective for patients with intermittent
claudication than walking advice alone in improving walk-
ing distance, WIQ scores, and quality of life as assessed in
the relevant domains of the SF-36. A supervised exercise
program should be made available for all patients with
intermittent claudication.
APPENDIX
The EXITPAD Study Group participants. Saskia
Table III. Results for Walking Improvement Questionnai
Instrument
WA
Baseline 12 mon
P
valueb
WIQ
Distance 0.36  0.22 0.57  0.30 .001 0
Speed 0.43  0.20 0.51  0.22 .001 0
Stairs 0.58  0.27 0.69  0.28 .001 0
Total score 0.46  0.17 0.59  0.24 .001 0
SF-36
Physical function 52.4  15.0 59.0  19.0 .001
Physical role 51.0  40.8 55.8  39.8 .71
Pain 52.0  18.0 55.8  22.7 .36
General health 54.9  13.0 54.2  12.8 .53
Physical summary score 35.2  8.1 37.7  8.8 .01
Social function 79.9  19.6 75.4  25.3 .06
Emotional role 85.1  29.0 82.4  34.9 .81
Mental health 76.4  17.2 74.6  19.1 .25
Vitality 63.0  20.3 59.2  19.8 .05
Mental summary score 55.9  9.9 53.0  11.4 .006
SET, Supervised exercise therapy; WA, walking advice.
aData at 3, 6, and 9 months are not shown.
bRepeated measurements analysis of variance.
cRepeated measurements analysis of covariance with baseline measurementP. A. Nicolaï, MD, PhD, Joep A. W. Teijink, MD, PhD,Edith M. Willigendael, MD, PhD, Bianca L. W. Bender-
macher, MD, PhD, Lotte M. Kruidenier, MD, PhD, Man-
uela Joore, PhD, Rob J. van Det, MD, Paul J. G. Jörning,
MD, PhD, Anco Vahl,MD, PhD,MsC, Rudolph P. Tutein
Nolthenius, MD, PhD, Philippe W. M. Cuypers, MD,
PhD, Marie-Louise E. L. Bartelink, MD, PhD, Erik J. M.
Hendriks, PhD, Rob A. de Bie, PhD, and Martin H. Prins,
MD, PhD.
Participating centers. Participating investigators
and number of patients (in parenthesis) included in the
EXITPAD study. The Netherlands: J. A. W. Teijink and
A. Habets, Atrium Medical Centre Parkstad, Heerlen
(125); R. J. van Det, A. Stam, and M. Blokhuis, Medical
Spectrum Twente, Enschede (46); P. J. G. Jörning, I.
Siebelt, L. Kasperink, and R. Haze, Isala Klinieken,
Zwolle (30); A. C. Vahl and J. M. de Vries, Onze Lieve
Vrouwe Gasthuis, Amsterdam (27); R. P. Tutein
Nolthenius, I. Nicaise, and P. de Jong, Albert Schweitzer
Hospital, Dordrecht (23); P. W. M. Cuypers and G.
Kiebert, Catharina Hospital, Eindhoven (22); L. H. J.
van den Akker and W. Hermans, Orbis Medical Centre,
Sittard (14); M. G. Samyn, G. de Bruijn, S. van Roij-
Piredda, and S. Wijnands, VieCurie, Venlo (7); P. Brum-
mel, S. Brandwijk, and P. Kosters, Franciscus Hospital,
Roosendaal (6); Th. A. A. van den Broek, G. A. Vos, M.
van Boxtel, and R. Smit, Waterland Hospital, Purmerend
(3); and G. H. Ho, L. Schoones, and M. Oerlemans,
Amphia Hospital, Breda (1).
We thank all patients who participated in the EXITPAD
study and the investigators who assisted at collaborating
IQ) and Short Form 36 (SF-36) Health Surveya
SET
P
valuecnge Baseline 12 mon
P
valueb Change
0.34 0.34  0.25 0.68  0.27 .001 0.34  0.30 .007
0.23 0.45  0.22 0.58  0.22 .001 0.13  0.24 .005
0.29 0.61  0.27 0.76  0.24 .001 0.15  0.26 .085
0.23 0.47  0.20 0.67  0.21 .001 0.21  0.21 .004
18.5 52.8  14.3 65.1  16.8 .001 12.3  18.3 .004
49.4 45.8  39.1 65.3  36.2 .001 16.6  45.2 .19
26.6 51.1  16.6 64.8  22.5 .001 13.4  24.5 .002
14.0 53.7  12.6 53.6  14.3 .10 0.7  13.5 .82
10.3 34.6  7.1 40.4  8.4 .001 5.8  8.6 .02
27.4 77.1  22.8 81.7  22.8 .04 4.3  26.6 .09
41.5 85.2  32.6 86.1  29.1 .80 0.3  38.7 .31
15.6 75.5  17.8 74.9  20.3 .42 0.3  16.8 .15
18.7 61.6  18.7 62.0  18.9 .46 –0.6  17.5 .17
10.1 55.3  10.5 53.5  10.4 .009 –1.8  10.4 .38
ariate.re (W
Cha
.21 
.10 
.11 
.13 
6.6 
4.8 
3.9 
–0.7 
2.5 
–4.5 
–2.7 
–1.8 
–3.9 
–2.8 sites.
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